A Study Comparing Two Anti-inflammatory Medications Naproxen or Aspirin for Cancer Prevention in Lynch Syndrome identifier:
NCT05411718 (

Prevention study for people with Lynch syndrome

Study Contact Information:

For additional information, please contact MD Anderson Cancer Center
Eduardo Vilar-Sanchez, MD by phone: (713) 563-4743 or Email: [email protected]

About the Study

The trial is enrolling people with Lynch syndrome. On average, the length of this study will last one year from the start of enrollment to completion. The study will measure  the effect of naproxen or aspirin on the immune cells in the gastrointestinal tract of people with Lynch syndrome. The trial will also evaluate any symptoms from the medications and any other changes of the colon and rectum.

What the Study Involves

This clinical trial is for people with Lynch Syndrome who have no active cancer. People who have never had a cancer diagnosis may participate. People who have previously been diagnosed with cancer may participate if they completed treatment at least 6 months prior to joining the study, and they have enough of their colon and/or rectum remaining to undergo colonoscopy or sigmoidoscopy.  People will be randomly divided into one of two groups:

Group 1: People in this group will:

Group 2: People in this group will:

Study Site


MD Anderson Cancer Center                                                                                                           
Principal Investigator/Contact: Eduardo Vilar Sanchez, MD [email protected]

This Study is Open To:

People 18 years of age or older may participate if they:

This Study is Not Open To:

People who:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.